Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H S Wasan

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Journal of Pathology|October 15, 1998
APC in the regulation of intestinal crypt fissionH S Wasan, H S Park, K C Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 2, 2001
SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathwayK L Woodford-Richens, A J Rowan, P Gorman, et al.
ESMO Open|December 25, 2021
Results of a single-arm pilot study of <sup>32</sup>P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapyP J Ross, H S Wasan, D Croagh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3S Kopetz, J Tabernero, S Lonardi, et al.
ESMO Open|June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trialA Lamarca, D H Palmer, H S Wasan, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Journal of Pathology|October 15, 1998
APC in the regulation of intestinal crypt fissionH S Wasan, H S Park, K C Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 2, 2001
SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathwayK L Woodford-Richens, A J Rowan, P Gorman, et al.
ESMO Open|December 25, 2021
Results of a single-arm pilot study of <sup>32</sup>P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapyP J Ross, H S Wasan, D Croagh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3S Kopetz, J Tabernero, S Lonardi, et al.
ESMO Open|June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trialA Lamarca, D H Palmer, H S Wasan, et al.
Pageof 2